ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.62
0.96%
US Tech 100
18,064.80
0.02%
S&P 500
5,277.51
0.80%
US Dollar vs CAD
1.36525
-0.01%
Bitcoin
67,622.04
0.21%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Eterna Therapeutics Inc (ERNA)

  7. Eterna Therapeutics Inc (ERNA) News

ERNA

Eterna Therapeutics (ERNA)

Eterna Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ERNA
DateTimeSourceHeadlineSymbolCompany
05/14/20244:14PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
05/10/20247:00AMGlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
05/08/20248:31AMGlobeNewswire Inc.Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory BoardNASDAQ:ERNAEterna Therapeutics Inc
05/07/20247:00AMGlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M LocusNASDAQ:ERNAEterna Therapeutics Inc
05/07/20247:00AMGlobeNewswire Inc.Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs iNASDAQ:ERNAEterna Therapeutics Inc
02/20/20247:30AMGlobeNewswire Inc.Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of DirectorsNASDAQ:ERNAEterna Therapeutics Inc
02/16/20244:30PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
02/16/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
01/31/20246:05AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
01/24/20243:15PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ERNAEterna Therapeutics Inc
01/22/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ERNAEterna Therapeutics Inc
01/19/20243:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
01/19/20249:31AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
01/16/20243:16PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ERNAEterna Therapeutics Inc
01/12/20243:49PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ERNAEterna Therapeutics Inc
01/03/20244:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
01/03/20244:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
01/03/20244:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
01/03/20243:15PMGlobeNewswire Inc.Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)NASDAQ:ERNAEterna Therapeutics Inc
12/22/202311:05AMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ERNAEterna Therapeutics Inc
12/20/20233:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
12/20/20233:15PMGlobeNewswire Inc.Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive OfficerNASDAQ:ERNAEterna Therapeutics Inc
12/20/20232:24PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ERNAEterna Therapeutics Inc
12/20/20239:05AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
12/18/20238:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
12/14/20235:56PMGlobeNewswire Inc.Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant FinancingNASDAQ:ERNAEterna Therapeutics Inc
12/14/20233:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
11/16/20233:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ERNAEterna Therapeutics Inc
11/13/20234:30PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ERNAEterna Therapeutics Inc
11/13/20237:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ERNAEterna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ERNA

Your Recent History

LSE
BW36
Citi Fun 25
BIT
P20SM8
NLBNPIT20SM8 20240621 220
BIT
P1TU05
NLBNPIT1TU05 20240621 180
BIT
UI079B
Unicredit Bank
EU
SGFZ
Societe Generale Domesti...
USOTC
PHCG
Pure Harvest Corporate (PK)
TSXV
RBE
RockBridge Resources Inc.
LSE
LMI3
Mstr 3xl �
TSX
RIB.UN
Ridgewood Canadian Inves...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved